Compositions and methods targeting the nucleotide free state of RAS to block oncogenic signaling and transformation

Inventors

O'Bryan, John • Koide, Shohei • Koide, Akiko

Assignees

MUSC Foundation for Research and Development • New York University • United States Department of Veterans Affairs

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12565537-B2

Patent

Publication Date

2026-03-03

Expiration Date


Abstract

The invention provides compositions and methods for binding Ras in a nucleotide free state (apo RAS) and inhibiting Ras signaling. In one embodiment, the invention provides monobodies that specifically bind apo RAS and methods of use. Thus, in diseases and conditions where a reduction of Ras signaling is beneficial, such inhibitory compositions act as therapeutics.

Core Innovation

The invention provides a composition that includes at least one molecule having a monobody domain that selectively binds RAS in a nucleotide free state (apo RAS) but not RAS in the nucleotide-bound state. The monobody domain comprises a sequence selected from the group consisting of SEQ ID NO: 1-6.

Related embodiments include fusion protein or peptide compositions that incorporate the apo RAS-selective monobody domain. The fusion protein can further include either a therapeutic agent or a detection moiety, and nucleic acid, expression vector, and host cell embodiments are also provided.

The disclosure is described as enabling therapeutic inhibition of Ras signaling and diagnostic measurement of apo RAS levels in biological samples. It is further described as applicable to screening Ras modulators and includes supporting examples directed to selective binding to apo-state RAS mutants and to functional consequences on Ras signaling, including ERK-MAPK activation and CRAF/RAF signaling.

Claims Coverage

The independent claim covers one inventive feature: an apo RAS-selective monobody-domain composition with sequence selection from SEQ ID NO: 1-6, distinguishing apo (nucleotide free) versus nucleotide-bound RAS. Dependent claims extend the composition into fusion/peptide, nucleic-acid, expression-vector, and host-cell formats, with optional therapeutic-agent or detection-moiety fusion.

A monobody-domain composition that selectively binds nucleotide-free (apo) RAS

A composition comprising at least one molecule comprising a monobody domain that selectively binds RAS in a nucleotide free state (apo RAS) but not RAS in the nucleotide-bound state, wherein the monobody domain comprises a sequence selected from the group consisting of SEQ ID NO: 1-6.

The claim set is centered on a monobody domain that distinguishes apo RAS from nucleotide-bound RAS via SEQ ID NO: 1-6, with dependent embodiments extending to fusion proteins/peptides, nucleic acids, expression vectors, and host cells, and optionally adding a therapeutic agent or detection moiety.

Stated Advantages

Selectively binds RAS in a nucleotide free state (apo RAS) but not RAS in the nucleotide-bound state.

Documented Applications

Therapeutic inhibition of Ras signaling, including effects on ERK-MAPK activation and CRAF/RAF signaling.

Diagnostic measurement of apo RAS levels in biological samples.

Screening for Ras modulators.

Combination therapy concepts.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.